Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that a notice that a Clinical Use Patent for the drug candidate arfolitixorin will be approved in Europe. The patent covers a dose regimen for treating solid tumors, such as colorectal, stomach, breast and liver cancer and expires in 2038.